<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03906539</url>
  </required_header>
  <id_info>
    <org_study_id>T/EMF/Pharma/18/23</org_study_id>
    <nct_id>NCT03906539</nct_id>
  </id_info>
  <brief_title>Effect of Virgin Coconut Oil (VCO) on Cardiometabolic Parameters in Patients With Dyslipidemia</brief_title>
  <official_title>Effect of Virgin Coconut Oil (VCO) on Cardiometabolic Parameters in Patients With Dyslipidemia: A Randomized, add-on, Placebo-controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>All India Institute of Medical Sciences, Bhubaneswar</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Coconut Development Board, Government of India</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>All India Institute of Medical Sciences, Bhubaneswar</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present research will help to assess the effect of virgin coconut oil on cholesterol
      level and also will help to know whether virgin coconut oil can reduce the risk of heart
      diseases or not.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dyslipidemia is a well-established risk factor for cardiovascular (CV) diseases. Lipid
      abnormalities, including high levels of low-density lipoprotein cholesterol (LDL-C), elevated
      triglycerides and low levels of high-density lipoprotein cholesterol (HDL-C), are independent
      predictors of CV disease. The National Cholesterol Education Program Adult Treatment Panel
      III (ATP III) guideline and the American College of Cardiology (ACC) and American Heart
      Association (AHA) guideline recommend the use of statins for primary prevention based on a
      patient's cardiovascular risk profile and low-density lipoprotein cholesterol (LDL-C) level.
      However, statin therapy may be insufficient for patients with mixed dyslipidemia, especially
      those with metabolic syndromes. While the addition of niacin, fibrate or ezetimibe may be
      useful in this setting, the combination therapy may lead to more adverse drug reactions.

      Virgin Coconut Oil (VCO), a nutraceutical, is an oil obtained from the fresh, mature kernel
      of the coconut by mechanical or natural means, with or without the use of heat and without
      undergoing chemical refining and it contains a considerable amount of medium-chain fatty
      acids similar to those in mother's milk. The beneficial effects of VCO in the reduction of
      cardiovascular risk have been proved from previous animal and clinical studies. The previous
      study demonstrated the potential beneficiary effect of VCO in lowering lipid levels in serum
      and LDL oxidation by physiological oxidants and this property of VCO was attributed to the
      biologically active polyphenol components present in the oil. It has been also demonstrated
      the hypolipidemic effect of VCO through activation of lipoprotein lipase, lecithin
      cholesterol acyltransferase and enhanced formation of bile acids. It was found that isolated
      polyphenols from VCO can prevent cadmium-induced lipid abnormalities and cardiovascular risk
      ratios by improving antioxidant defence systems. VCO may improve cardiovascular and hepatic
      complications in obesity. The findings from another study suggest a beneficial eï¬€ect of VCO
      on lipid profile, renal status, hepatic antioxidant defence system, and cardiovascular risk
      indices in rats. It has been observed that VCO increased HDL-C level in patients with
      coronary artery disease (CAD). In a randomized crossover trial, it was found that daily
      consumption of VCO in young healthy adults significantly increased high-density lipoprotein
      cholesterol without any safety issues.

      Our literature search revealed that to date, no clinical trial evaluated the potential of VCO
      as an add-on hypolipidemic agent in patients suffering from dyslipidemia. So, the present
      clinical trial has been designed to evaluate the effect of VCO on cardiometabolic parameters
      as an add-on with statins in patients with dyslipidemia.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 22, 2019</start_date>
  <completion_date type="Anticipated">March 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in serum High Density Lipoprotein (HDL)</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Will be measured by autoanalyser</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in serum Lipoprotein (a)</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Will be measured by ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Atherogenic index</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Ratio of LDL cholesterol and HDL cholesterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Coronary risk index</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Ratio of total cholesterol and HDL cholesterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Cardiovascular risk index</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Ratio of triglyceride and HDL cholesterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in visceral fat</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Will be analysed by by digital body fat analyser</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in lipid peroxidation</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Thiobarbituric acid reactive substances (TBARS) will be estimated by spectrofluorometric method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum Low Density Lipoprotein (LDL)</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Will be measured by autoanalyser</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum Very Low Density Lipoprotein (VLDL)</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Will be measured by autoanalyser</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum total cholesterol</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Will be measured by autoanalyser</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum triglyceride</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Will be measured by autoanalyser</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Dyslipidemias</condition>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The patients in control groups will receive tablet atorvastatin (10 mg/day) and a placebo capsule.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VCO Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The VCO group will receive capsule VCO (1000mg/day) as an add-on to tablet atorvastatin (10 mg/day).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin 10mg</intervention_name>
    <description>Atorvastatin 10 mg per day</description>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_label>VCO Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Virgin Coconut Oil (VCO)</intervention_name>
    <description>Capsule VCO (1000 mg/day)</description>
    <arm_group_label>VCO Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsule - 1 capsule per day</description>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with dyslipidemia [diagnosis of dyslipidemia is made when either of the lipid
             abnormality is present: LDL-C &gt;140mg/dl, HDL-C &lt;40mg/dl, Triglyceride &gt;150mg/dl
             according to diagnostic criteria of dyslipidemia ]

          -  Patients aged 18-65 years, of either sex.

          -  Treatment-naive patients or patients who had not taken any treatment for at least 2
             weeks before inclusion.

        Exclusion Criteria:

          -  History of any cardiovascular diseases, stroke, diabetes, malignancy, musculoskeletal
             or hepatic diseases

          -  History of hypersensitivity to statins or coconut oil

          -  Patients who are already under treatment for the presenting conditions.

          -  Patients with drug/alcohol abuse.

          -  Pregnant and nursing women.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>RITUPARNA MAITI, MD</last_name>
    <phone>09438884191</phone>
    <email>pharm_rituparna@aiimsbhubaneswar.edu.in</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>RASHMI R MOHANTY, MD</last_name>
    <email>genmed_rashmi@aiimsbhubaneswar.edu.in</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>AIIMS, Bhubaneswar</name>
      <address>
        <city>Bhubaneshwar</city>
        <state>Odisha</state>
        <zip>751019</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>RITUPARNA MAITI, MD</last_name>
      <email>rituparnamaiti@gmail.com</email>
    </contact>
    <investigator>
      <last_name>RASHMI R MOHANTY, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <results_reference>
    <citation>Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L; INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004 Sep 11-17;364(9438):937-52.</citation>
    <PMID>15364185</PMID>
  </results_reference>
  <results_reference>
    <citation>Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, Jacobs DR Jr, Bangdiwala S, Tyroler HA. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation. 1989 Jan;79(1):8-15.</citation>
    <PMID>2642759</PMID>
  </results_reference>
  <results_reference>
    <citation>Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G, Wareham N, Bingham S, Boekholdt SM, Khaw KT, Gudnason V. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation. 2007 Jan 30;115(4):450-8. Epub 2006 Dec 26.</citation>
    <PMID>17190864</PMID>
  </results_reference>
  <results_reference>
    <citation>Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA. 2007 Jul 18;298(3):309-16.</citation>
    <PMID>17635891</PMID>
  </results_reference>
  <results_reference>
    <citation>Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ; National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004 Jul 13;110(2):227-39. Review. Erratum in: Circulation. 2004 Aug 10;110(6):763.</citation>
    <PMID>15249516</PMID>
  </results_reference>
  <results_reference>
    <citation>Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC Jr, Watson K, Wilson PW, Eddleman KM, Jarrett NM, LaBresh K, Nevo L, Wnek J, Anderson JL, Halperin JL, Albert NM, Bozkurt B, Brindis RG, Curtis LH, DeMets D, Hochman JS, Kovacs RJ, Ohman EM, Pressler SJ, Sellke FW, Shen WK, Smith SC Jr, Tomaselli GF; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014 Jun 24;129(25 Suppl 2):S1-45. doi: 10.1161/01.cir.0000437738.63853.7a. Epub 2013 Nov 12. Erratum in: Circulation. 2014 Jun 24;129(25 Suppl 2):S46-8. Erratum in: Circulation. 2015 Dec 22;132(25):e396.</citation>
    <PMID>24222016</PMID>
  </results_reference>
  <results_reference>
    <citation>Famurewa AC, Ekeleme-Egedigwe CA, Nwali SC, Agbo NN, Obi JN, Ezechukwu GC. Dietary Supplementation with Virgin Coconut Oil Improves Lipid Profile and Hepatic Antioxidant Status and Has Potential Benefits on Cardiovascular Risk Indices in Normal Rats. J Diet Suppl. 2018 May 4;15(3):330-342. doi: 10.1080/19390211.2017.1346031. Epub 2017 Aug 17.</citation>
    <PMID>28816548</PMID>
  </results_reference>
  <results_reference>
    <citation>Nevin KG, Rajamohan T. Beneficial effects of virgin coconut oil on lipid parameters and in vitro LDL oxidation. Clin Biochem. 2004 Sep;37(9):830-5.</citation>
    <PMID>15329324</PMID>
  </results_reference>
  <results_reference>
    <citation>Arunima S, Rajamohan T. Virgin coconut oil improves hepatic lipid metabolism in rats--compared with copra oil, olive oil and sunflower oil. Indian J Exp Biol. 2012 Nov;50(11):802-9.</citation>
    <PMID>23305031</PMID>
  </results_reference>
  <results_reference>
    <citation>[Should the specialist examination be introduced? Thoughts of the Education Committee]. Ugeskr Laeger. 1969 Jan 23;131(4):170-1. Danish.</citation>
    <PMID>5787998</PMID>
  </results_reference>
  <results_reference>
    <citation>Panchal SK, Carnahan S, Brown L. Coconut Products Improve Signs of Diet-Induced Metabolic Syndrome in Rats. Plant Foods Hum Nutr. 2017 Dec;72(4):418-424. doi: 10.1007/s11130-017-0643-0.</citation>
    <PMID>29079969</PMID>
  </results_reference>
  <results_reference>
    <citation>Cardoso DA, Moreira AS, de Oliveira GM, Raggio Luiz R, Rosa G. A COCONUT EXTRA VIRGIN OIL-RICH DIET INCREASES HDL CHOLESTEROL AND DECREASES WAIST CIRCUMFERENCE AND BODY MASS IN CORONARY ARTERY DISEASE PATIENTS. Nutr Hosp. 2015 Nov 1;32(5):2144-52. doi: 10.3305/nh.2015.32.5.9642.</citation>
    <PMID>26545671</PMID>
  </results_reference>
  <results_reference>
    <citation>Chinwong S, Chinwong D, Mangklabruks A. Daily Consumption of Virgin Coconut Oil Increases High-Density Lipoprotein Cholesterol Levels in Healthy Volunteers: A Randomized Crossover Trial. Evid Based Complement Alternat Med. 2017;2017:7251562. doi: 10.1155/2017/7251562. Epub 2017 Dec 14.</citation>
    <PMID>29387131</PMID>
  </results_reference>
  <results_reference>
    <citation>Teramoto T, Sasaki J, Ueshima H, Egusa G, Kinoshita M, Shimamoto K, Daida H, Biro S, Hirobe K, Funahashi T, Yokote K, Yokode M; Japan Atherosclerosis Society (JAS) Committee for Epidemiology and Clinical Management of Atherosclerosis. Diagnostic criteria for dyslipidemia. Executive summary of Japan Atherosclerosis Society (JAS) guideline for diagnosis and prevention of atherosclerotic cardiovascular diseases for Japanese. J Atheroscler Thromb. 2007 Aug;14(4):155-8.</citation>
    <PMID>17827859</PMID>
  </results_reference>
  <results_reference>
    <citation>Ermakova GL, Abakumov EM, Martynova VA. [Immunological and microbiological parallels in pneumonia complicating leukemia]. Klin Med (Mosk). 1973 Feb;51(2):29-32. Russian.</citation>
    <PMID>4700825</PMID>
  </results_reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>April 5, 2019</study_first_submitted>
  <study_first_submitted_qc>April 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 8, 2019</study_first_posted>
  <last_update_submitted>June 8, 2020</last_update_submitted>
  <last_update_submitted_qc>June 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>All India Institute of Medical Sciences, Bhubaneswar</investigator_affiliation>
    <investigator_full_name>RITUPARNA MAITI</investigator_full_name>
    <investigator_title>Additional Professor</investigator_title>
  </responsible_party>
  <keyword>Cardiometabolic parameters</keyword>
  <keyword>Virgin coconut oil</keyword>
  <keyword>Serum lipoprotein</keyword>
  <keyword>Lipid peroxidation</keyword>
  <keyword>Atorvastatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

